• Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia. 

  Wang, H-Q; Jia, L; Li, Y-T; Farren, T; Agrawal, SG; Liu, F-T (2019-01-08)

  Chronic lymphocytic leukemia (CLL) remains incurable with current standard therapy. We have previously reported that an increased expression of interleukin-6 (IL-6) receptor CD126 leads to resistance of CLL cells to ...

• Lamin B1 regulates somatic mutations and progression of B-cell malignancies 

  Klymenko, T; Bloehdorn, J; Bahlo, J; Robrecht, S; Akylzhanova, G; Cox, K; Estenfelder, S; Wang, J; Edelmann, J; Strefford, JC (2018-02)

• Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma 

  Maybury, B; Cook, G; Pratt, G; Yong, K; Ramasamy, K (Elsevier BV, 2016-11)

• Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant 

  Araf, S; Wang, J; Ashton-Key, M; Korfi, K; Di Bella, D; Rio-Machin, A; Odabashian, M; Foria, V; Du, M-Q; Cucco, F (2019-03-31)

• Precision medicine and lymphoma 

  Heward, JA; Kumar, EA; Korfi, K; Okosun, J; Fitzgibbon, J (2018-07)

• Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. 

  Davies, JK; Brennan, LL; Wingard, JR; Cogle, CR; Kapoor, N; Shah, AJ; Dey, BR; Spitzer, TR; de Lima, M; Cooper, LJ (2018-09-01)

  Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is a curative treatment for many hematologic cancers. Use of haploidentical (mismatched) donors increases HSCT availability but is limited by severe ...

• GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML. 

  Al Seraihi, AF; Rio-Machin, A; Tawana, K; Bödör, C; Wang, J; Nagano, A; Heward, JA; Iqbal, S; Best, S; Lea, N (2018-11)

• Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia 

  Cornely, OA; Leguay, T; Maertens, J; Vehreschild, MJGT; Anagnostopoulos, A; Castagnola, C; Verga, L; Rieger, C; Kondakci, M; Haerter, G (2017-08)

• Predicting early relapse in follicular lymphoma: have we turned a corner? 

  Araf, S; Okosun, J; Fitzgibbon, J (2018-04)

• Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma 

  Araf, S; Wang, J; Korfi, K; Pangault, C; Kotsiou, E; Rio-Machin, A; Rahim, T; Heward, J; Clear, A; Iqbal, S (2018-05)

• Stabilization of the metaphase spindle by Cdc14 is required for recombinational DNA repair 

  Teresa Villoria, M; Ramos, F; Duenas, E; Faull, P; Rodriguez Cutillas, P; Clemente-Blanco, A (2017-01-04)

• Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial) 

  Chanan-Khan, A; Egyed, M; Robak, T; Martinelli de Oliveira, FA; Echeveste, MA; Dolan, S; Desjardins, P; Blonski, JZ; Mei, J; Golany, N (2017-05)

• Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma 

  Mackay, A; Burford, A; Carvalho, D; Izquierdo, E; Fazal-Salom, J; Taylor, KR; Bjerke, L; Clarke, M; Vinci, M; Nandhabalan, M (2017-10-09)

• Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia 

  Passaro, D; Di Tullio, A; Abarrategi, A; Rouault-Pierre, K; Foster, K; Ariza-McNaughton, L; Montaner, B; Chakravarty, P; Bhaw, L; Diana, G (2017-09-11)

• Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. 

  Burgermeister, E; Höde, P; Betge, J; Gutting, T; Merkel, A; Wu, W; Tänzer, M; Mossner, M; Nowak, D; Magdeburg, J (2017-10-17)

  Colorectal cancer (CRC) is a biologically and clinically heterogeneous disease. Even though many recurrent genomic alterations have been identified that may characterize distinct subgroups, their biological impact and ...

• The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. 

  Di Tullio, A; Rouault-Pierre, K; Abarrategi, A; Mian, S; Grey, W; Gribben, J; Stewart, A; Blackwood, E; Bonnet, D (2017-11-22)

  Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overriding AraC resistance in AML remains an unmet medical need. Here we show that the CHK1 inhibitor (CHK1i) GDC-0575 enhances ...

• The Ageing Brain: Effects on DNA Repair and DNA Methylation in Mice 

  Langie, SAS; Cameron, KM; Ficz, G; Oxley, D; Tomaszewski, B; Gorniak, JP; Maas, LM; Godschalk, RWL; van Schooten, FJ; Reik, W (2017-02)

• Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors 

  Horton, SJ; Giotopoulos, G; Yun, H; Vohra, S; Sheppard, O; Bashford-Rogers, R; Rashid, M; Clipson, A; Chan, W-I; Sasca, D (2017-09)

• Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL 

  Fransecky, L; Neumann, M; Heesch, S; Schlee, C; Ortiz-Tanchez, J; Heller, S; Mossner, M; Schwartz, S; Mochmann, LH; Isaakidis, K (2016-09-22)

• Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report 

  Passweg, JR; Baldomero, H; Bader, P; Bonini, C; Duarte, RF; Dufour, C; Gennery, A; Kroeger, N; Kuball, J; Lanza, F (2017-06)

View more